Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008 (2008), Article ID 316306, 11 pages
http://dx.doi.org/10.1155/2008/316306
Research Article

Statins Activate Human PPAR 𝛼 Promoter and Increase PPAR 𝛼 mRNA Expression and Activation in HepG2 Cells

1Department of Biochemistry, Faculty of Medicine, Saitama Medical University, Saitama 350-0495, Japan
2Department of Endocrinology and Diabetes, Faculty of Medicine, Saitama Medical University, Saitama 350-0495, Japan
3Department of Physiology, Faculty of Medicine, Saitama Medical University, Saitama 350-0495, Japan
4Molecular Clock Project, Research Center for Genomic Medicine, Saitama Medical University, Saitama 350-0495, Japan

Received 17 June 2008; Revised 17 September 2008; Accepted 2 October 2008

Academic Editor: Howard Glauert

Copyright © 2008 Makoto Seo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. S. Brown and J. L. Goldstein, “A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 20, pp. 11041–11048, 1999. View at Publisher · View at Google Scholar
  2. P. Fan, B. Zhang, S. Kuroki, and K. Saku, “Pitavastatin, a potent hydroxymethylglutaryl coenzyme a reductase inhibitor, increases cholesterol 7 α-hydroxylase gene expression in HepG2 cells,” Circulation Journal, vol. 68, no. 11, pp. 1061–1066, 2004. View at Publisher · View at Google Scholar
  3. A. Saiki, T. Murano, F. Watanabe, T. Oyama, Y. Miyashita, and K. Shirai, “Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes,” Journal of Atherosclerosis and Thrombosis, vol. 12, no. 3, pp. 163–168, 2005. View at Google Scholar
  4. A. Tonkin, P. Aylward, D. Colquhoun et al., “Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris,” The American Journal of Cardiology, vol. 76, no. 7, pp. 474–479, 1995. View at Publisher · View at Google Scholar
  5. C. M. Ballantyne, A. G. Olsson, T. J. Cook, M. F. Mercuri, T. R. Pedersen, and J. Kjekshus, “Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S,” Circulation, vol. 104, no. 25, pp. 3046–3051, 2001. View at Publisher · View at Google Scholar
  6. L. Streja, C. J. Packard, J. Shepherd, S. Cobbe, and I. Ford, “Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS),” The American Journal of Cardiology, vol. 90, no. 7, pp. 731–736, 2002. View at Publisher · View at Google Scholar
  7. U. Laufs, D. Marra, K. Node, and J. K. Liao, “3-hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down-regulation of p27Kip1,” The Journal of Biological Chemistry, vol. 274, no. 31, pp. 21926–21931, 1999. View at Publisher · View at Google Scholar
  8. M. Takemoto, M. Kitahara, K. Yokote et al., “NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells,” British Journal of Pharmacology, vol. 133, no. 1, pp. 83–88, 2001. View at Publisher · View at Google Scholar · View at PubMed
  9. Q. Ding, T. Hayashi, A. J. Packiasamy et al., “The effect of high glucose on NO and O2- through endothelial GTPCH1 and NADPH oxidase,” Life Sciences, vol. 75, no. 26, pp. 3185–3194, 2004. View at Publisher · View at Google Scholar · View at PubMed
  10. M. Christ, J. Bauersachs, C. Liebetrau, M. Heck, A. Günther, and M. Wehling, “Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation,” Diabetes, vol. 51, no. 8, pp. 2648–2652, 2002. View at Publisher · View at Google Scholar
  11. I. Inoue, S.-I. Goto, K. Mizotani et al., “Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells,” Life Sciences, vol. 67, no. 8, pp. 863–876, 2000. View at Publisher · View at Google Scholar
  12. K. Schoonjans, B. Staels, and J. Auwerx, “The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation,” Biochimica et Biophysica Acta, vol. 1302, no. 2, pp. 93–109, 1996. View at Publisher · View at Google Scholar
  13. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar
  14. K. L. Gearing, M. Gottlicher, M. Teboul, E. Widmark, and J. A. Gustafsson, “Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 4, pp. 1440–1444, 1993. View at Publisher · View at Google Scholar
  15. S. Mandard, M. Müller, and S. Kersten, “Peroxisome proliferator-activated receptor α target genes,” Cellular and Molecular Life Sciences, vol. 61, no. 4, pp. 393–416, 2004. View at Publisher · View at Google Scholar · View at PubMed
  16. S. Kersten, “Peroxisome proliferator activated receptors and lipoprotein metabolism,” PPAR Research, vol. 2008, Article ID 132960, 11 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
  17. T. Aoki, Y. Yoshinaka, H. Yamazaki et al., “Triglyceride-lowering effect of pitvastatin in a rat model of postprandial lipemia,” European Journal of Pharmacology, vol. 444, no. 1-2, pp. 107–113, 2002. View at Publisher · View at Google Scholar
  18. S. J. Nicholls, E. M. Tuzcu, I. Sipahi et al., “Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study),” The American Journal of Cardiology, vol. 97, no. 11, pp. 1553–1557, 2006. View at Publisher · View at Google Scholar · View at PubMed
  19. M. S. Kostapanos, H. J. Milionis, K. G. Lagos, C. B. Rizos, A. D. Tselepis, and M. S. Elisaf, “Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia,” European Journal of Pharmacology, vol. 590, no. 1–3, pp. 327–332, 2008. View at Publisher · View at Google Scholar · View at PubMed
  20. A. Planavila, J. C. Laguna, and M. Vazquez-Carrera, “Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-κB activation,” Biochimica et Biophysica Acta, vol. 1687, no. 1-3, pp. 76–83, 2005. View at Google Scholar
  21. D. Zapolska-Downar, A. Siennicka, M. Kaczmarczyk, B. Kołodziej, and M. Naruszewicz, “Simvastatin modulates TNFα-induced adhesion molecules expression in human endothelial cells,” Life Sciences, vol. 75, no. 11, pp. 1287–1302, 2004. View at Publisher · View at Google Scholar · View at PubMed
  22. J.-F. Landrier, C. Thomas, J. Grober et al., “Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-α-dependent,” The Journal of Biological Chemistry, vol. 279, no. 44, pp. 45512–45518, 2004. View at Publisher · View at Google Scholar · View at PubMed
  23. I. P. Torra, Y. Jamshidi, D. M. Flavell, J.-C. Fruchart, and B. Staels, “Characterization of the human PPARα promoter: identification of a functional nuclear receptor response element,” Molecular Endocrinology, vol. 16, no. 5, pp. 1013–1028, 2002. View at Publisher · View at Google Scholar
  24. I. Inoue, K. Hayashi, F. Yagasaki et al., “Apoptosis of endothelial cells may be mediated by genes of peroxisome proliferator-activated receptor γ1 (PPARγ1) and PPARα genes,” Journal of Atherosclerosis and Thrombosis, vol. 10, no. 2, pp. 99–108, 2003. View at Google Scholar
  25. I. Inoue, Y. Shinoda, M. Ikeda et al., “CLOCK/BMAL1 is involved in lipid metabolism via transactivation of the peroxisome proliferator-activated receptor (PPAR) response element,” Journal of Atherosclerosis and Thrombosis, vol. 12, no. 3, pp. 169–174, 2005. View at Google Scholar
  26. J. B. Lundbye and P. D. Thompson, “Statin use in the metabolic syndrome,” Current Atherosclerosis Reports, vol. 7, no. 1, pp. 17–21, 2005. View at Publisher · View at Google Scholar
  27. W. Palinski, “New evidence for beneficial effects of statins unrelated to lipid lowering,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 1, pp. 3–5, 2001. View at Google Scholar
  28. R. Kleemann, H. M. G. Princen, J. J. Emeis et al., “Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin,” Circulation, vol. 108, no. 11, pp. 1368–1374, 2003. View at Publisher · View at Google Scholar · View at PubMed
  29. O. Grip, S. Janciauskiene, and S. Lindgren, “Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes,” Inflammation Research, vol. 51, no. 2, pp. 58–62, 2002. View at Publisher · View at Google Scholar
  30. M. Gottlicher, E. Widmark, Q. Li, and J. A. Gustafsson, “Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4653–4657, 1992. View at Publisher · View at Google Scholar
  31. B. G. Lake, “Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals,” Annual Review of Pharmacology and Toxicology, vol. 35, pp. 483–507, 1995. View at Publisher · View at Google Scholar · View at PubMed
  32. P. Dowell, J. E. Ishmael, D. Avram, V. J. Peterson, D. J. Nevrivy, and M. Leid, “p300 functions as a coactivator for the peroxisome proliferator-activated receptor α,” The Journal of Biological Chemistry, vol. 272, no. 52, pp. 33435–33443, 1997. View at Publisher · View at Google Scholar
  33. Y. Zhu, C. Qi, S. Jain, M. S. Rao, and J. K. Reddy, “Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor,” The Journal of Biological Chemistry, vol. 272, no. 41, pp. 25500–25506, 1997. View at Publisher · View at Google Scholar
  34. P. Puigserver, Z. Wu, C. W. Park, R. Graves, M. Wright, and B. M. Spiegelman, “A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis,” Cell, vol. 92, no. 6, pp. 829–839, 1998. View at Publisher · View at Google Scholar
  35. C. K. Glass, “Going nuclear in metabolic and cardiovascular disease,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 556–560, 2006. View at Publisher · View at Google Scholar · View at PubMed